Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of BOT+BAL before colon-cancer surgery, its central development priority. The shift is backed by ...

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Earlier this month, Agenus released three-year landmark Phase 1b data showing that its botensilimab plus balstilimab combination produced clinically meaningful long-term survival and durable responses in heavily pretreated patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. An especially interesting finding was the plateau in the Kaplan-Meier survival curve beyond two years and the proportion of patients alive and off systemic...

Agenus expects to receive about $85 million soon under a placement, with the potential for another $255 million later.

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS)...

Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer. Founder, Chairman and Chief Executive Off

Private Placement Strengthens Funding PositionAgenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million private placement designed to strengthen its balance sheet and support the continued development of its clinical pipeline.

Investors will balance renewed geopolitical tensions against a busy week for inflation data and the start of bank earnings season

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

Investing.com - U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space.